TITLE:
Strontium-89 Therapy for Breast Cancer Bone Metastases: Pain Relief Effects and Predictive Factors
AUTHORS:
Yukinori Okada, Tatsuyuki Abe, Mio Shinozaki, Shinjiro Sakaino, Hiromichi Gomi, Yasuo Nakajima, Yasuyuki Kojima, Tomoko Uejima, Koichiro Tsugawa
KEYWORDS:
Breast Cancer, 89-Sr, Analgesia
JOURNAL NAME:
Advances in Breast Cancer Research,
Vol.7 No.4,
October
10,
2018
ABSTRACT: In this study, we evaluate the analgesic effect of strontium-89 (Sr-89)
for patients with breast cancer having multiple bone metastases and identify
positive predictive factors. We retrospectively evaluated 15 patients who were
administered Sr-89 for painful bone metastases from breast cancer at St. Marianna
University Hospital between January 2010 and April 2014. For patients receiving
multiple doses, only the first dose was evaluated. Pain relief was defined as a
decrease in the score of the Numeric Rating Scale (NRS) or requirement of
reduced doses of pain medication 1 - 2 months after being on Sr-89
administration. The associations between pain relief owing to Sr-89 and that
owing to bone scan index, interval from bone metastasis onset to Sr-89
administration, zoledronate and denosumab treatment history, hormone
therapy/aromatase inhibitor history, and chemotherapy history were assessed. A
logistic model was used for statistical analysis. Pain relief was observed in
11 (73.3%) of 15 patients. No statistically significant value was observed between
pain relief and bone scan index, interval from bone metastasis onset to Sr-89
administration, zoledronate and denosumab treatment history, hormone
therapy/aromatase inhibitor history, and chemotherapy. Thus, Sr-89 was
effective for 70% of patients with breast cancer bone metastases, although
positive predictive factors for pain relief could not be determined.